Endocrine Abstracts

Aim: Check-point inhibitors have revolutionized cancer treatment while introducing a new spectrum of immune-related adverse effects. Hyperglycemia is frequently observed shortly after initiation of immunotherapy. While immune-mediated type 1 diabetes mellitus is currently the only defined condition associated with post-immunotherapy hyperglycemia, it includes only a small fraction of cases (an estimated prevalence of 0.5%). This study was aimed to determine factors associated ...